Pulmatrix, Inc. · NASDAQ:PULM
Pulmatrix — Investor Presentation (January 2024)
30 slides from Pulmatrix's investor presentation, Jan 8, 2024
Slide 1: Pulmatrix
PULMATRixX NASDAQ: PULM
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements. All statements other than statements of historical fact contained herein, including statements regarding our business plans or strategies, projected or anticipated benefits or other consequences of our plans or strategies, projected
Slide 3: Pulmatrix mission and iSPERSE technology
7 {| ae PULMATRIixX PULMATRIiX is committed to the development and commercialization of novel and transformational medicines for patients all over the world, using our proprietary iSPERSE™ technology to optimally deliver both respiratory and non-respiratory therapies via the respiratory system.
Slide 4: Pursuing Strategic Alternatives that Leverage the Company's Pipeline, iSPERSE and Cash
PULM (NASDAQ) Pursuing Strategic Alternatives that Leverage the Company’s Pipeline, iSPERSE Technology and Cash on Hand © Proprietary iSPERSE™ platform technology that seeks to optimize pharmacokinetics and pharmacology in respiratory and non-respiratory therapeutics. © Ascalable platform with appli
Slide 5: Management Team
Management Team Deep expertise in respiratory diseases & drug delivery technology across all stages of development Ted Raad — CEO & Director © Previously Chief Business Officer of Pulmatrix © 20 years of commercial healthcare and life ‘sciences leadership experience © Former Chief Commercial Officer
Slide 6: Credentialed Board of Directors
Credentialed Board of Directors Board of directors with extensive experience in public and private life sciences companies Michael J. Higgins - Chairman Ted/Raad:- CEO &!Dreoior ‘© Entrepreneur-in-residence at Polaris Partners and Board Member ‘* Previously Chief Business Officer of Pulmatrix of Voy
Slide 7: iSPERSE Enabled Pipeline
iSPERSE Enabled Pipeline PUR3100 Ph2 Ready (IND Ac -d) puR Acate Merane my senaareres PUR1800 Acute Exacerbations in Chronic : RRS Kinase Inhibitor Obstructive Pulmonary Disease Pursuing Permership to Advance (NSKI) (AECOPD) PUR1900 Allergic Bronchopulmonary Closing Ph2b at 8 subjects with CSR estim
Slide 8: iSPERSE
iSPERSE Small Dense and Dispersible Engineered Dry Powder Proprietary Technology
Slide 9: iSPERSE Platform
iSPERSE Platform Small, dense and dispersible particles designed for highly efficient respiratory delivery SPE! E Enables Sick Patients to Get More Effective Doses red Dry Powd ine otential RSE Advantages | Evolution of © Can be used with a broad range of drugs, small molecule to biologic © Can be u
Slide 10: PUR3100
PUR3100 Inhaled Dihydroergotamine (DHE) for Treatment of Acute Migraine ~$575M U.S. peak net revenue, a 1% total Rx share, is a conservative forecast! iSPERSE mitigates the manufacturing / device issues resulting in the MAP0004 FDA complete response Ph1 results: Safe, well tolerated, 5-minute T,,.,
Slide 11: PUR3100: Acute Treatment of Migraine
PUR3100: Acute Treatment of Migraine Large underserved market Large Market >1 billion worldwide >38 million U.S. Affects 3x's more women than men at | PULMATRixX is an investigational drug, the safety an Large Unmet Medical Need 75% of patients not actively treated with Rx’s due to poor efficacy 80%
Slide 12: Migraine — Inhaled DHE Therapy Potential Advantages
Migraine — Pu Inhaled DHE Therapy Potential Advantages What Do Patients Want? Dosing Fast onset of action Migraine upon 24+ hour headache Inhaled preferred Absence of: through early Tray. awakening, quick to relief through over intranasal, nausea, lethargy, and sustained peak intensity, rescue susta
Slide 13: PUR3100 Phase 1 Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics
PUR3100 Phase 1 Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics Objective to demonstrate safety and comparative bioavailability of PUR3100 (pulmonary inhaled) relative to |V DHE ly in 24 Healthy Voluntee ndomized Double-blind, Double-dummy Single Dose St . Inhaled Placebo + 4mg
Slide 14: PUR3100 Achieved All Phase 1 Study Objectives and Goals
PUR3100 Achieved All Phase 1 Study Objectives and Goals Related to the Target Product Profile (TPP) Objective: To determine the safety and tolerability of single doses of inhaled PUR3100 in healthy adult subjects Objective: To characterize the systemic pharmacokinetics (PK) of single doses of inhale
Slide 15: PUR3100 Four Hour Exposure Profile is Similar to IV DHE
PUR3100 Four Hour Exposure Profile is Similar to |1V DHE Equivalent T,,., with C,,., below the range typically associated with elevated nausea risk —® IVDHE 1.0 mg © Tinax iS at the first time point (5 min) for “= PUR31000.5 mg all subjects at all PUR3100 doses Trae “4 PURS100 1.0™mg “+ PURS100 1.5
Slide 16: Published Non-Sub-Q Pain Freedom Data Earlier Than Two Hours
Published Non-Sub-Q Pain Freedom Data Earlier Than Two Hours Pain Freedom above Placebo (%) Drug/Route Class. Dose = eae F O.5hour 1hour 2hour 24 hour " Risatriptan sma 0 i 22 13 60" TabletWafert:2 omg 7 5 A 76 55 ‘Sumatriptan rt Nasal Spraye_| Titan 20mg - 10 a - 62 ‘Sumatriptan [50mg - A 47 10 50!
Slide 17: PUR3100 Kinetics Compared to MAP0004
PUR3100 Kinetics Compared to MAP0004 “= MAPOO04 1 mg -=+ MAP0004 2 mg — PUR3100 0.5 mg — PUR3100 1.0 mg © Tinax At 5 min for all PUR3100 doses Trex Tmax — PUR3100 1.5 mg versus 12 minutes in MAP Phase 1 : > 50% Nausea study" 15000 4. 7 e Ahigher C,,,, was achieved with PUR3100 ‘Therapeutic Window’ e
Slide 18: PUR3100 Kinetics vs. Marketed DHE Therapies
PUR3100 Kinetics vs. Marketed DHE Therapies max Trax Trax © Tax at 5 min for all PUR3100 doses versus 30 minutes for in INP1041 and 47 minutes for = IN Mgranal 2mg + INPIO04 145mg 15000 PuR3to0 05mg Pura%00 10mg S i euros 15g Migranal' zZ ‘Therapeutic Window © Higher C,,., than published 2 1500 intr
Slide 19: PUR3100: No Vomiting and Less Nausea Than IV DHE
PUR3100: No Vomiting and Less Nausea Than IV DHE 454mg, 4 ‘chest tightness 454mg. 7112000. El “suprapubic pain ° 454mg. 400000. 3 Vomit 451mg 50800 4 451mg. 49100 4 . 451mg) 25300 5 Vomit 454mg. 44700 4 PUR3100 15mg 19300 5. ° PURS100 15mg 718800 4 PURS100 15 mg 4700 6 PURS1001.5 mg 44500 4 ° PURS10
Slide 20: PUR3100 Potential Development Plan Through Phase 3
PUR3100 Potential Development Plan Through Phase 2 Phase 2 data will inform the design and likelihood of a single Phase 3 study aa a a3 aa qu @ 3 aa an Ph3 CTM Readiness FPD TR Phase 2 Study Design Powered Phase 2 followed by single Phase 3 Phase 2 randomized (1:11), double-blind, placebo-controlled
Slide 21: PUR3100: $575M Peak Net Revenue Potential at LOE in the U.S.
PUR3100: $575M Peak Net Revenue Potential at LOE in the U.S. Physician and Patient Feedback Payer Feedback % of patients on triptan experiencing 4 | a suboptimal response 59) generic treatment % of patients ranking “starts to show 7 failures required improvement by 30 minutes” as the | 44% #1 most i
Slide 22: PUR1800
PUR1800 Inhaled p38, Syk, Src Kinase Inhibitor with Potential for Treating AECOPD. NSKI Portfolio In-Licensed from Janssen, Including RV1162 RV1162 Reformulated Into iSPERSE Enabled PUR1800 PUR1800 represents up to ~$2.4B" peak net KZ revenue opportunity in the U.S. as an inhaled non- steroidal trea
Slide 23: Limited Efficacy in Standard of Care for AECOPD
Limited Efficacy in Standard of Care for AECOPD Moderate-to-Severe Exacerbations Significant unmet need exists in AECOPD with underlying infection and/or steroid resistance e Steroids are standard of care for moderate-to- severe acute exacerbations, which occur across all patient severity types Noni
Slide 24: Narrow Spectrum Kinase Inhibitors (NSKI)
Narrow Spectrum Kinase Inhibitors (NSKI) Block steroid-resistant inflammation and lung remodeling processes Treat Steroid-Resistant Inflammation @ © Inhibit p38 MAP kinases (p38MAPK) to restore steroid sensitivity and reduce inflammation © Block inflammatory action of Src, which promotes cytokine pr
Slide 25: RV1162 (NSKI) Reduces Steroid-Resistant Inflammation in Preclinical Models
RV1162 (NSKI) Reduces Steroid-Resistant Inflammation in Preclinical Models RV1162 reduces steroid insensitive, tobacco smoke-induced inflammation and restores steroid efficacy e Verified kinase target engagement and inhibition with similar potency across p38, Src and Syk kinases e Reduces steroid-se
Slide 26: PUR1800 Phase 1b Trial in Stable COPD Preliminary Results
PUR1800 Phase 1b Trial in Stable COPD Preliminary Results Objectives of safety and pharmacokinetics were completed Randomized, double-blind, 3-way crossover study; 3 Dose Groups (2 active, 1 placebo) with 15 pts. 14 days of daily dosing, with 28-day crossover and 28-day follow-up Endpoints « Safety
Slide 27: PUR1800: $2.4B in U.S. Peak Revenue Potential
PUR1800: $2.4B in U.S. Peak Revenue Potential e ~16M COPD patients in the U.S. Treat irren' Epecied ise ° 77% experience at least one exacerbation annually PUR1800 a ~18M moderate-to-severe AECOPD episodes Guoral corticosteroids anton antibiotics) ul annually in U.S. Oral Corticosteroids + Antibioti
Slide 28: Chronic Toxicology Pathology Results Support Potential Expansion Into Chronic Treatment
Chronic Toxicology Pathology Results Support Potential Expansion Into Chronic Treatment of Pulmonary Disease (ex. COPD, IPF, Asthma) Severe Asthma Rare Disease <100K in US* AECOPD 48M Moderate to Severe Acute Exacerbation per yearin US? ~10M Adults in US? , (50% of Adult . 1 109 Asthma) ug/kg/day in
Slide 29: PUR1900
PUR1900 Inhaled Antifungal Cipla Worldwide Partnership Inhaled Itraconazole to Treat Allergic Bronchopulmonary Aspergillosis (ABPA) in Patients with Asthma iSPERSE enables itraconazole delivery to the lung, providing PUR1900 potential to address the underlying cause of disease while avoiding side ef
Slide 30: Pulmatrix
PULMATRixX NASDAQ: PULM